Literature DB >> 15201746

Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer.

Paul D Sved1, Pablo Gomez, M Manoharan, Sandy S Kim, Mark S Soloway.   

Abstract

PURPOSE: We examined the implications of underestimating Gleason score by prostate biopsy in patients with biopsy Gleason 6 prostate cancer with respect to adverse pathological findings and biochemical recurrence after radical prostatectomy.
MATERIALS AND METHODS: We retrospectively reviewed clinical and pathological data on a cohort of 531 patients with Gleason score 6 on prostate biopsy who underwent radical retropubic prostatectomy between June 1992 and January 2002. Patients were excluded if they received neoadjuvant androgen deprivation. Concordance between biopsy and radical prostatectomy Gleason score was examined. A comparison was made with respect to final radical prostatectomy specimen pathology and the risk of biochemical recurrence between cases that remained Gleason 6 and those with a final grade of 7 or greater.
RESULTS: A total of 451 patients were included in the analysis. Mean followup was 55.1 months (range 12 to 123.4). Of the patients 184 (41%) had a Gleason score of 7 or greater after a review of the entire prostate, while 37 (8%) had a score of less than 6 and 230 remained with Gleason 6. Patients who were under graded were more likely to have extraprostatic extension (22% vs 4%, p <0.01), seminal vesicle invasion (9% vs 2%, p <0.01) and biochemical recurrence (10% vs 3%, p <0.01) compared to those who remained with Gleason score 6.
CONCLUSIONS: Gleason grade on needle biopsy is an inexact predictor of the final grade following radical prostatectomy. Patients with biopsy Gleason score 6 who are under graded are at significantly higher risk for adverse pathological features and biochemical recurrence than patients who remain with Gleason score 6 or less on final pathology findings.

Entities:  

Mesh:

Year:  2004        PMID: 15201746     DOI: 10.1097/01.ju.0000132135.18093.d6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  26 in total

1.  Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.

Authors:  Joan Alexander; Jude Kendall; Jean McIndoo; Linda Rodgers; Robert Aboukhalil; Dan Levy; Asya Stepansky; Guoli Sun; Lubomir Chobardjiev; Michael Riggs; Hilary Cox; Inessa Hakker; Dawid G Nowak; Juliana Laze; Elton Llukani; Abhishek Srivastava; Siobhan Gruschow; Shalini S Yadav; Brian Robinson; Gurinder Atwal; Lloyd C Trotman; Herbert Lepor; James Hicks; Michael Wigler; Alexander Krasnitz
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

2.  Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.

Authors:  Raphaele Renard Penna; Geraldine Cancel-Tassin; Eva Comperat; Pierre Mozer; Priscilla Léon; Justine Varinot; Morgan Roupret; Marc-Olivier Bitker; Olivier Lucidarme; Olivier Cussenot
Journal:  World J Urol       Date:  2016-02-22       Impact factor: 4.226

3.  Temporal changes in the pathologic assessment of prostate cancer.

Authors:  M Scott Lucia; Adrie van Bokhoven
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

4.  Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology.

Authors:  Jesse D Le; Samuel Stephenson; Michelle Brugger; David Y Lu; Patricia Lieu; Geoffrey A Sonn; Shyam Natarajan; Frederick J Dorey; Jiaoti Huang; Daniel J A Margolis; Robert E Reiter; Leonard S Marks
Journal:  J Urol       Date:  2014-05-01       Impact factor: 7.450

5.  Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.

Authors:  Ekaterina Olkhov-Mitsel; Theodorus Van der Kwast; Ken J Kron; Hilmi Ozcelik; Laurent Briollais; Christine Massey; Franz Recker; Maciej Kwiatkowski; Neil E Fleshner; Eleftherios P Diamandis; Alexandre R Zlotta; Bharati Bapat
Journal:  Epigenetics       Date:  2012-08-09       Impact factor: 4.528

6.  The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era.

Authors:  Stavros Sfoungaristos; Ioannis Katafigiotis; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

7.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

8.  Upgrading of Gleason score on radical prostatectomy specimen compared to the pre-operative needle core biopsy: an Indian experience.

Authors:  Rishi Nayyar; Prabhjot Singh; Narmada P Gupta; Ashok K Hemal; Prem N Dogra; Amlesh Seth; Rajeev Kumar
Journal:  Indian J Urol       Date:  2010 Jan-Mar

9.  Clinical and pathological variables that predict changes in tumour grade after radical prostatectomy in patients with prostate cancer.

Authors:  Stavros Sfoungaristos; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

10.  [Active surveillance of localized prostate cancer. Significance of prostate core needle biopsies].

Authors:  J Rüschoff; P Middel; P Albers
Journal:  Pathologe       Date:  2008-09       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.